Analysis of therapeutic effect and prognostic factors of non-small cell lung cancer leptomeningeal metastasis patients treated by epidermal growth factor receptor tyrosine kinase inhibitors
10.3760/cma.j.issn.1673-4904.2017.11.001
- VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌脑膜转移患者的疗效及预后影响因素分析
- Author:
Yuqin GAO
1
;
Ruihua XU
;
Fengmei WEI
;
Qian SHAO
Author Information
1. 济宁医学院附属湖西医院肿瘤科
- Keywords:
Carcinoma,non-small-cell lung;
Neoplasm metastasis;
Receptor,epidermal growth factor;
Tyrosine kinase inhibitor
- From:
Chinese Journal of Postgraduates of Medicine
2017;40(11):961-965
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and prognostic factors of non-small cell lung cancer (NSCLC) leptomeningeal metastasis (LM) patients undergoing treatment with epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs).Methods The clinical data of 30 patients with NSCLC- LM were retrospectively analyzed, including the basic situation, survival time, clinical characteristics,pathological type,differentiation degree and treatment method.The median survival time (MOS) was calculated by Kaplan-Meier method. The log-rank test was used to analyze the prognostic single factors.The Cox regression model was used to analyze the multivariate factors. Results The log-rank test result showed that sex,pathological type,differentiation degree and EGFR-TKIs treatment were the influencing factors of MOS(P<0.05).The multivariate analysis result showed that sex,pathological type, differentiation degree and EGFR-TKIs treatment were the independent influencing factors of prognosis in NSCLC-LM patients (P<0.05), and the female gender (RR = 0.090, 95% CI 0.048 -0.140),adenocarcinoma(RR=0.108,95% CI 0.073-0.134),well differentiation(RR=0.112,95% CI 0.076 - 0.141), using EGFR-TKIs treatment (RR = 0.042, 95% CI 0.012 - 0.074) were significant predictors of a good prognosis. Conclusions The female gender, well differentiation, adenocarcinoma and EGFR-TKIs treatments are significant predictors of a good prognosis. EGFR-TKIs can prolong the survival time of patients with NSCLC-LM,and it is recommended for a clinical treatment for patients with NSCLC-LM.
